





medicines
patent
pool



THE MEDICINES PATENT POOL
EXPANDING ACCESS TO PUBLIC HEALTH


Mission

Increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries (LMICs) through voluntary licensing and patent pooling.

We work with a range of partners – civil society, international organisations, industry, patient groups and governments – to prioritise and license novel and existing medicines and health technologies for people in these countries.

Vision

A world in which people in need in LMICs have rapid access to effective and affordable medical treatments and health technologies.



abbvie

Boehringer
Ingelheim



Bristol-Myers Squibb



GILEAD

Janssen



MSD



NIH

lopinavir
ritonavir
(adults)
lopinavir
ritonavir
(paediatrics)

nevirapine
(non-assert)

atazanavir

bictegravir
cobicistat
elvitegravir
emtricitabine
tenofovir
alafenamide
tenofivir
disoproxil

darunavir
(paediatric non-assert)

raltegravir
(paediatric)

darunavir
related



ViiV
Healthcare



Roche



UNIVERSITY OF
LIVERPOOL

abbvie



Bristol-Myers Squibb



PHARCO
CORPORATION



JOHNS HOPKINS
UNIVERSITY

abacavir
(paediatrics)
dolutegravir
(paediatrics)
dolutegravir
(adults)

valganciclovir
(pricing agreement)

Solid drug
nanoparticles
technology

glecaprevir/
pibrentasvir

daclastavir

ravidasvir


sutezolid



medicines
patent
pool


MPP IMPACT ANALYSIS: HIV (2012-2018)

June 2019




Total patient-years (HIV): 21.3 million

*Source: confidential sales data by licensees




Total patient-years (HIV): 21.3 million


*Source: confidential sales data by licensees



Total HIV-related cost-savings by 2018: \$883 million




Total number of packs sold: 36.9 million




72% of MPP's HIV-related impact (cost-savings) is derived from TLE, TLD, & DTG

***TLE:** tenofovir disoproxil fumarate (TDF), lamivudine (3TC) & efavirenz (EFV); **TLD:** tenofovir disoproxil fumarate (TDF), lamivudine (3TC) & dolutegravir (DTG); **TE:** tenofovir disoproxil fumarate (TDF) & emtricitabine (FTC); **TL:** tenofovir disoproxil fumarate (TDF) & lamivudine (3TC); **TEE:** tenofovir disoproxil fumarate (TDF), emtricitabine (FTC) & efavirenz (EFV); **ATV/r:** atazanavir & ritonavir; **LPV/r:** lopinavir & ritonavir




*Sub-Saharan Africa (SSA): non-identified countries by which sales were made through procurement agents

Note: Analysis excludes countries where <5,000 patient-years of treatment were sold




**Sub-Saharan Africa (SSA): non-identified countries by which sales were made through procurement agents*

Note: Analysis excludes countries where <60,000 packs of treatment were sold



*Data source: <https://aidsinfo.unaids.org/>



**Sub-Saharan Africa (SSA): non-identified countries by which sales were made through procurement agents*

Over 50% of DTG-derived sales are in non-specified SSA countries, South Africa, and Kenya

COUNTRIES (61)

Anguilla	Congo	India	Moldova	Syria
Argentina	Congo, Dem. Rep.	Iran	Morocco	Tanzania
Armenia	Cote d'Ivoire	Jamaica	Mozambique	Uganda
Bahamas	Cuba	Kenya	Myanmar	Ukraine
Barbados	Dominican Republic	Kyrgyzstan	Namibia	Uzbekistan
Bolivia	Egypt	Laos	Nepal	Venezuela
Botswana	El Salvador	Lebanon	Nigeria	Yemen
Burkina Faso	Equatorial Guinea	Lesotho	Pakistan	Zambia
Burundi	Gabon	Liberia	Paraguay	Zimbabwe
Cambodia	Georgia	Madagascar	Rwanda	
Cameroon	Guatemala	Malawi	Saint Lucia	
Cape Verde	Guyana	Mali	South Africa	
Chile	Haiti	Mauritius	Swaziland	

*Analysis include sales of DTG 50mg and TDF/3TC/DTG